{"filing":{"accession_number":"0001193125-26-257365","cik":"0001563880","ticker":"TRVI","company_name":"Trevi Therapeutics, Inc.","form":"8-K","filing_date":"2026-06-04","report_date":null,"primary_document":"trvi-20260603.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1563880/000119312526257365/trvi-20260603.htm"},"events":[{"id":6794,"run_id":5953,"accession_number":"0001193125-26-257365","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"summary":"Stockholders voted on five proposals at the June 3, 2026 Annual Meeting: election of Michael Heffernan as a Class I director, ratification of Ernst \u0026 Young LLP as auditor, advisory approval of named executive officer compensation, approval of the Amended and Restated 2019 Stock Incentive Plan increasing available shares by 8,000,000, and approval of an amendment to increase authorized common shares from 200 million to 400 million. All proposals passed with detailed vote tallies disclosed.","company_name":"Trevi Therapeutics, Inc.","ticker":"TRVI","filing_date":"2026-06-04","form":"8-K","submitted_at":null,"items":[{"id":4317,"accession_number":"0001193125-26-257365","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of an Amended and Restated 2019 Stock Incentive Plan, which increases available shares by 8,000,000 and modifies compensation arrangements including non-employee director compensation limits and dividend/vesting provisions. This is a material compensatory arrangement disclosure under Item 5.02(e), affecting equity-based compensation for executives and directors.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:56:26.718644+00:00","company_name":"","ticker":null,"filing_date":""},{"id":4318,"accession_number":"0001193125-26-257365","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The disclosure reports stockholder approval and effectiveness of an amendment to increase authorized common shares from 200 million to 400 million. While this is a structural change that could facilitate future dilutive issuances, the amendment itself is a routine capital structure adjustment that does not fit the more specific event categories. The materiality lies in the potential for future dilution rather than an immediate material event, making this a borderline case best classified as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:56:26.718644+00:00","company_name":"","ticker":null,"filing_date":""},{"id":4319,"accession_number":"0001193125-26-257365","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This is a clear disclosure of shareholder voting results from the June 3, 2026 Annual Meeting under Item 5.07, covering five proposals: election of Michael Heffernan as a Class I director, ratification of Ernst \u0026 Young LLP as auditor, advisory approval of named executive officer compensation, approval of the A\u0026R 2019 Plan, and approval of an amendment to increase authorized shares from 200 million to 400 million. The detailed vote tallies (For, Against, Abstain, Broker Non-Votes) for each proposal are the hallmark of shareholder_vote_results disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:56:26.718644+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":4317,"accession_number":"0001193125-26-257365","item_number":"5.02","item_title":"Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers","event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure centers on stockholder approval of an Amended and Restated 2019 Stock Incentive Plan, which increases available shares by 8,000,000 and modifies compensation arrangements including non-employee director compensation limits and dividend/vesting provisions. This is a material compensatory arrangement disclosure under Item 5.02(e), affecting equity-based compensation for executives and directors.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:56:26.718644+00:00","company_name":"Trevi Therapeutics, Inc.","ticker":"TRVI","filing_date":"2026-06-04"},{"id":4318,"accession_number":"0001193125-26-257365","item_number":"5.03","item_title":"Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year","event_type":"other_material","event_domain":"catchall","is_material":true,"confidence":0.65,"reasoning":"The disclosure reports stockholder approval and effectiveness of an amendment to increase authorized common shares from 200 million to 400 million. While this is a structural change that could facilitate future dilutive issuances, the amendment itself is a routine capital structure adjustment that does not fit the more specific event categories. The materiality lies in the potential for future dilution rather than an immediate material event, making this a borderline case best classified as other_material.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:56:26.718644+00:00","company_name":"Trevi Therapeutics, Inc.","ticker":"TRVI","filing_date":"2026-06-04"},{"id":4319,"accession_number":"0001193125-26-257365","item_number":"5.07","item_title":"Submission of Matters to a Vote of Security Holders","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.95,"reasoning":"This is a clear disclosure of shareholder voting results from the June 3, 2026 Annual Meeting under Item 5.07, covering five proposals: election of Michael Heffernan as a Class I director, ratification of Ernst \u0026 Young LLP as auditor, advisory approval of named executive officer compensation, approval of the A\u0026R 2019 Plan, and approval of an amendment to increase authorized shares from 200 million to 400 million. The detailed vote tallies (For, Against, Abstain, Broker Non-Votes) for each proposal are the hallmark of shareholder_vote_results disclosures.","classifier_version":"claude-haiku-4-5-20251001+prompt-9e0ffca5","taxonomy_version":"v1","classified_at":"2026-06-05T04:56:26.718644+00:00","company_name":"Trevi Therapeutics, Inc.","ticker":"TRVI","filing_date":"2026-06-04"}]}